Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Talks Extended in Swiss Company’s Takeover of Toronto-based Patheon

By Pharmaceutical Processing | September 28, 2009

BASEL, Switzerland — Talks have been extended in Swiss drug company Lonza Group’s takeover bid for Toronto-based drugmaker Patheon. In a statement released early Monday, a special committee of independent directors of Patheon and Lonza announced the extension until Oct. 15. Lonza, which is offering US$3.55 per share or $485 million, is the white knight bidder for Patheon, which had been fighting against an earlier hostile bid by New York private equity firm JLL. JLL is Patheon’s largest shareholder. While JLL’s own bid expired in August, it has explicitly stated that with 57 per cent ownership of Patheon shares, it can and will block the Lonza deal. For its part, Patheon has said it may be able to go ahead with the Lonza bid without the approval of JLL because Lonza may be willing to waive the condition that it receive at least two-thirds of all shares under the offer. Meantime, Patheon will try to hold a special shareholder meeting Dec. 15. But one possible hitch in that plan is a legal challenge filed by shareholders Joaquin Viso and Olga Lizardi, which seeks an order requiring the meeting to be held no later than Oct. 30. Patheon has said it will fight that challenge in court. Patheon is a global provider of contract development and manufacturing services to the pharmaceutical industry, providing such services to more than 300 pharmaceutical and biotechnology companies.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE